2024 ASCO® Annual Meeting Insights Hub

Meeting coverage & Vumedi’s exclusive highlights, all in one place.

 

ASCO® 2024 Insights: "KEYNOTE-942 Trial - 3-Year Update on mRNA-4157 & Pembro in Resected Melanoma"

222 views
June 12, 2024

Chapters

KEYNOTE-942 Trial & mRNA-4157 Overview

00:00

Trial Design & Patient Eligibility

02:49

3-Year Treatment Results & Survival Data

04:22

Safety Profile & Biomarker Analyses

06:56

0 Comments
Login to view comments. Click here to Login